News
Latest press releases – plus an archive of press releases, thus recording milestones and key facts in Sunstone’s history.
Galecto Announces First Patient Treated in Phase 2a Trial of the Oral LOXL2 Inhibitor GB2064 in Myelofibrosis (the MYLOX-1 Trial)
Galecto, Inc. (NASDAQ: GLTO), a biotechnology company focused on the development of novel treatments for fibrosis and cancer, today announced the treatment of the first patient in a Phase 2a trial of its oral LOXL2 inhibitor GB2064 in myelofibrosis. Myelofibrosis, a...
Synendos Therapeutics Expands Series A to CHF 24 million with new investment
Synendos Therapeutics is thrilled to announce an extension to the Series A financing with the addition of Ysios Capital to its syndicate of European investors. Ysios Capital’s contribution brings the total raised to CHF 24 million, following a Series A financing...
Alligator Bioscience and MacroGenics Enter into a Research Collaboration to Develop a Novel Immunotherapy
Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it has entered into a joint research collaboration with MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
Step Pharma Raises EUR35 Million in Series B Financing to Advance First in Class CTPS1 inhibitor into the Clinic in T Cell Malignancies
Step Pharma, a biotech company developing novel drugs for oncology and autoimmune diseases, today announced the successful closing of a EUR35 million Series B financing. New investors Hadean Ventures and Sunstone Life Science Ventures co-led the round, joining...
Alligator Bioscience appoints Søren Bregenholt as new CEO
Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the Board of Directors has appointed Søren Bregenholt, Ph.D. as the company’s new Chief Executive Officer (CEO), to strengthen Alligator’s business development activities and clinical progress on an...
Ascelia Pharma has carried out a directed new share issue raising SEK 200 million
Ascelia Pharma AB (publ) (ticker: ACE) (“Ascelia Pharma” or the “Company”) has successfully carried out a directed new share issue of 5,000,000 ordinary shares at a subscription price of SEK 40 per share, subject to the approval of an Extra General Meeting (the...